Featured Insights and Perspectives from Darwin

The latest insights, ideas, and perspectives from Darwin, updated weekly. Explore a cross-section of up-to-date content from us and other thought leaders on trends in health care, research, and data.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

News and Insights

Showing items 1 to3 of 6

Playlist Category
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Our Take: Eisai, Biogen get another chance with FDA’s accelerated approval of Alzheimer’s drug lecanemab
Insight
Our Take Newsletter
January 9, 2023

Our Take: Eisai, Biogen get another chance with FDA’s accelerated approval of Alzheimer’s drug lecanemab

Learn More
January 9, 2023
Pharma strategy, engagement, and market access
Our Take: CVS Health reportedly in talks to acquire primary care provider Oak Street Health
Insight
Our Take Newsletter
January 16, 2023

Our Take: CVS Health reportedly in talks to acquire primary care provider Oak Street Health

Learn More
January 16, 2023
Value-based care and alternative payment models
Our Take: Optum’s expansion in value-based care contributes to UnitedHealth Group’s record $20.6 billion profit in 2022
Insight
Our Take Newsletter
January 23, 2023

Our Take: Optum’s expansion in value-based care contributes to UnitedHealth Group’s record $20.6 billion profit in 2022

Learn More
January 23, 2023
Value-based care and alternative payment models
Our Take: Elevance Health’s family of Blue Cross Blue Shield state plans will grow to 15 with acquisition of BCBS Louisiana
Insight
Our Take Newsletter
January 30, 2023

Our Take: Elevance Health’s family of Blue Cross Blue Shield state plans will grow to 15 with acquisition of BCBS Louisiana

Learn More
January 30, 2023
IDN trends, challenges, and leadership
Our Take: Appellate court sides with drugmakers in battle over 340B drug discounts to contract pharmacies
Insight
Our Take Newsletter
February 6, 2023

Our Take: Appellate court sides with drugmakers in battle over 340B drug discounts to contract pharmacies

Learn More
February 6, 2023
Pharmacy, PBMs and drug pricing
Our Take: CVS Health strikes a deal with Oak Street Health in its attempt to catch up with Walgreens and other competitors
Insight
Our Take Newsletter
February 13, 2023

Our Take: CVS Health strikes a deal with Oak Street Health in its attempt to catch up with Walgreens and other competitors

Learn More
February 13, 2023
IDN trends, challenges, and leadership
Our Take: CMS takes next steps toward lowering drug prices and improving access for Medicare and Medicaid enrollees
Insight
Our Take Newsletter
February 20, 2023

Our Take: CMS takes next steps toward lowering drug prices and improving access for Medicare and Medicaid enrollees

Learn More
February 20, 2023
Health policy, CMS initiatives and health economics
Our Take: Amazon, UnitedHealth Group complete their respective multibillion-dollar mergers
Insight
Our Take Newsletter
February 27, 2023

Our Take: Amazon, UnitedHealth Group complete their respective multibillion-dollar mergers

Learn More
February 27, 2023
IDN trends, challenges, and leadership
Our Take: UnityPoint Health, Presbyterian Healthcare Services sign LOI to explore $11 billion cross-market merger
Insight
Our Take Newsletter
March 6, 2023

Our Take: UnityPoint Health, Presbyterian Healthcare Services sign LOI to explore $11 billion cross-market merger

Learn More
March 6, 2023
IDN trends, challenges, and leadership
Our Take: Biden’s proposed budget seeks to further lower drug costs for seniors by building on provisions in the Inflation Reduction Act
Insight
Our Take Newsletter
March 13, 2023

Our Take: Biden’s proposed budget seeks to further lower drug costs for seniors by building on provisions in the Inflation Reduction Act

Learn More
March 13, 2023
Health policy, CMS initiatives and health economics
Our Take: Pfizer signs definitive agreement to acquire oncology-focused biotech Seagen for $43 billion
Insight
Our Take Newsletter
March 20, 2023

Our Take: Pfizer signs definitive agreement to acquire oncology-focused biotech Seagen for $43 billion

Learn More
March 20, 2023
Pharma strategy, engagement, and market access
Our Take: Update on Darwin Research Group
Insight
Our Take Newsletter
March 27, 2023

Our Take: Update on Darwin Research Group

Learn More
March 27, 2023
IDN trends, challenges, and leadership
Stay Aware. Stay Informed.

Want to stay ahead of health care trends?

Sign up for highly curated, expert weekly strategic insights for health care executives and leaders.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.